TherapeuticsMD enters $5M private placement with Rubric Capital

On May 1, 2023, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (the “Investor”), pursuant to which the Company agreed to sell to the Investor, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), from time to time during the term of the Subscription Agreement, at a purchase price of the five-day volume-weighted average price of the Company’s common stock at the time of the sale of such Shares, at an aggregate purchase price of up to $5,000,000 (collectively, the “Private Placement”).